Conjunctivitis in patients with atopic dermatitis treated with dupilumab is associated with higher baseline serum levels of immunoglobulin E and thymus and activation-regulated chemokine but not clinical severity in a real-world setting

Introduction Allergic rhinitis (AR) is one of the most common allergic diseases, which affects ~20% of the world's population. T-helper (Th) type 2 cells produce interleukin (IL) 4 and IL-13, and mediate allergic responses, and these cytokines have been extensively studied as key players in the atopic airway diseases. However, the involvement of Th17 cells and IL-17 in AR has not been clearly examined. Aim To reevaluate AR clinical severity with serum IL-17, whether IL-17 affects the disease alone or in contribution with the atopic predisposition. Patients and Methods During an 18-month period, 39 individuals were divided into three groups: A, (13 control), B (13 with mild-to-moderate AR), and C (13 with severe AR). Both group B and group C patients (26) were subjected to clinical examination and allergy skin testing, and to measurement of both total serum immunoglobulin E (IgE) and IL-17 levels. Eleven patients with AR then were exposed to 6 months of cluster immunotherapy, whereas the rest of the patients were not exposed. Results Revealed a significant elevation of serum IL-17 levels with an associated increase in serum IgE in the patients with AR compared with controls and revealed that the serum levels of both total serum IgE and IL-17 decreased significantly after cluster immunotherapy. Conclusion These preliminary results added new data about the use of injective immunotherapy as well as reported on the use of sublingual immunotherapy.

Download Full-text

Glycomacropeptide Attenuates Inflammation, Pruritus, and Th2 Response Associated with Atopic Dermatitis Induced by 2,4-Dinitrochlorobenzene in Rat

Journal of Immunology Research ◽

10.1155/2017/6935402 ◽

2017 ◽

Vol 2017 ◽

pp. 1-11 ◽

Cited By ~ 11

Author(s):

Fabiola Carolina Muñoz ◽

Maritza Montserrat Cervantes ◽

Daniel Cervantes-García ◽

Mariela Jiménez ◽

Javier Ventura-Juárez ◽

...

Keyword(s):

Atopic Dermatitis ◽

Inflammatory Process ◽

Skin Diseases ◽

Immunoglobulin E ◽

Alternative Therapy ◽

Serum Levels ◽

Inhibitory Effect ◽

Industrialized Countries ◽

Th2 Response ◽

Common Skin

Atopic dermatitis (AD) is one of the most common skin diseases, whose incidence is increasing in industrialized countries. The epicutaneous application of a hapten, such as 2,4-dinitrochlorobenzene (DNCB), evokes an experimental murine AD-like reaction. Glycomacropeptide (GMP) is a dairy bioactive peptide derived from hydrolysis ofκ-casein by chymosin action. It has anti-inflammatory, prebiotic, and immunomodulatory effects. The present study was aimed to investigate the effect of GMP administration on DNCB-induced AD in rats. The severity of inflammatory process, pruritus, production of cytokines, and total immunoglobulin E (IgE) content were measured, and the histopathological features were analyzed. GMP reduced the intensity of inflammatory process and edema of DNCB-induced dermatitis, with a significant decrease in eosinophils recruitment and mast cells hyperplasia. In addition GMP suppressed the serum levels of total IgE and IL-4, IL-5, and IL-13 expression in AD-lesions. Besides, the levels of IL-10 were significantly increased. Remarkably, GMP administration before AD-induction abolished pruritus in dermatitis-like reactions in the rats. Taken together, these results indicate that GMP has an inhibitory effect on AD by downregulating Th2 dominant immune response, suggesting GMP as a potential effective alternative therapy for the prevention and management of AD.

Download Full-text

Early Clinical Efficacy After Dupilumab Therapy for Adult Severe Atopic Dermatitis in a Real-World Setting

Journal of Allergy and Clinical Immunology ◽

10.1016/j.jaci.2020.12.140 ◽

2021 ◽

Vol 147 (2) ◽

pp. AB28

Author(s):

Paloma Poza Guedes ◽

Ruperto Gonzalez Perez ◽

Elena Mederos Luis ◽

Victor Matheu ◽

Cristina Alava ◽

...

Keyword(s):

Atopic Dermatitis ◽

Clinical Efficacy ◽

Real World ◽

Severe Atopic Dermatitis ◽

Real World Setting

Download Full-text

Vitamin D Deficiency and Effects of Vitamin D Supplementation on Disease Severity in Patients with Atopic Dermatitis: A Systematic Review and Meta-Analysis in Adults and Children

Nutrients ◽

10.3390/nu11081854 ◽

2019 ◽

Vol 11 (8) ◽

pp. 1854 ◽

Cited By ~ 10

Author(s):

Hattangdi-Haridas ◽

Lanham-New ◽

Wong ◽

Ho ◽

Darling

Keyword(s):

Systematic Review ◽

Vitamin D ◽

Atopic Dermatitis ◽

Meta Analysis ◽

Vitamin D Supplementation ◽

Clinical Severity ◽

Baseline Serum ◽

Hydroxyvitamin D ◽

Adults And Children ◽

25 Hydroxyvitamin D

Research has investigated 25-hydroxyvitamin D (25(OH)D) levels in the Atopic Dermatitis (AD) population, as well as changes in AD severity after vitamin D (VitD) supplementation. We performed an up-to-date systematic review and meta-analysis of these findings. Electronic searches of MEDLINE, EMBASE and COCHRANE up to February 2018 were performed. Observational studies comparing 25(OH)D between AD patients and controls, as well as trials documenting baseline serum 25(OH)D levels and clinical severity by either SCORAD/EASI scores, were included. Of the 1085 articles retrieved, sixteen were included. A meta-analysis of eleven studies of AD patients vs. healthy controls (HC) found a mean difference of −14 nmol/L (95% CI −25 to −2) for all studies and −16 nmol/L (95% CI −31 to −1) for the paediatric studies alone. A meta-analysis of three VitD supplementation trials found lower SCORAD by −11 points (95% CI −13 to −9, p < 0.00001). This surpasses the Minimal Clinical Important Difference for AD of 9.0 points (by 22%). There were greater improvements in trials lasting three months and the mean weighted dose of all trials was 1500–1600 IU/daily. Overall, the AD population, especially the paediatric subset, may be at high-risk for lower serum 25(OH)D. Supplementation with around 1600 IU/daily results in a clinically meaningful AD severity reduction.

Download Full-text

Correlation of serum interleukin-31 with pruritus and blood eosinophil markers in children with atopic dermatitis

Allergy and Asthma Proceedings ◽

10.2500/aap.2020.41.190016 ◽

2020 ◽

Vol 41 (1) ◽

pp. 59-65

Author(s):

Jung Hye Byeon ◽

Wonsuck Yoon ◽

So Hyun Ahn ◽

Hyo Sun Lee ◽

Seunghyun Kim ◽

...

Keyword(s):

Atopic Dermatitis ◽

Immunoglobulin E ◽

Eosinophil Cationic Protein ◽

Skin Inflammation ◽

Clinical Severity ◽

Blood Eosinophil ◽

Healthy Children ◽

Cationic Protein ◽

Clinical Biomarkers ◽

Significant Difference

Background: Atopic dermatitis (AD) is chronic pruritic inflammatory skin disease in children. Interleukin (IL) 31 is a recently discovered cytokine associated with chronic skin inflammation and pruritus. Objectives: The aims of this study were to determine whether serum IL-31 levels are increased in children with AD and to examine the relationship between IL-31 and other clinical biomarkers in AD. Methods: Serum cytokine levels, including IL-31, IL-4, and IL-12, were measured in 38 patients with AD and 10 healthy children. Peripheral blood eosinophils, serum immunoglobulin E levels, eosinophil cationic protein, and thymic stromal lymphopoietin (TSLP) were measured. We also estimated the clinical severity of AD by using the Scoring Atopic Dermatitis (SCORAD) index by a single clinician. Results: The serum IL-31 levels were significantly higher in the patients with AD than in the healthy children. IL-31 correlated well with the SCORAD index and blood eosinophilic inflammatory markers. The serum level of TSLP was also higher in patients with AD than in the healthy children; however, levels of IL-4 and IL-12 were not different between AD and healthy children. There was no significant difference in serum IL-31 levels between patients with atopic AD and nonatopic AD. Conclusion: This study showed that serum IL-31 levels were significantly elevated in patients with AD than in the healthy children and correlated well with disease severity. IL-31 seemed to be one of the cytokines that induce pruritus and eosinophilic inflammation in AD. Serum IL-31 correlated with pruritic symptoms and disease course of AD.

Download Full-text

Evaluation of dietary intake of vitamin E in the treatment of atopic dermatitis: a study of the clinical course and evaluation of the immunoglobulin E serum levels

International Journal of Dermatology ◽

10.1046/j.1365-4362.2002.01423.x ◽

2002 ◽

Vol 41 (3) ◽

pp. 146-150 ◽

Cited By ~ 63

Author(s):

Evridiki Tsoureli-Nikita ◽

Jana Hercogova ◽

Torello Lotti ◽

Giovanni Menchini

Keyword(s):

Atopic Dermatitis ◽

Vitamin E ◽

Dietary Intake ◽

Immunoglobulin E ◽

Clinical Course ◽

Serum Levels

Download Full-text

Atopic Dermatitis—Beyond the Skin

Diagnostics ◽

10.3390/diagnostics11091553 ◽

2021 ◽

Vol 11 (9) ◽

pp. 1553

Author(s):

Mădălina Mocanu ◽

Dan Vâță ◽

Anisia-Iuliana Alexa ◽

Laura Trandafir ◽

Adriana-Ionela Patrașcu ◽

...

Keyword(s):

Atopic Dermatitis ◽

Immunoglobulin E ◽

Negative Impact ◽

Systemic Disease ◽

Clinical Manifestations ◽

Allergic Diseases ◽

Serum Levels ◽

Chronic Inflammatory Disease ◽

Food Allergies ◽

Disease Category

Atopic dermatitis is a chronic inflammatory disease that can arise during the first months of life or at maturity and have a significant negative impact on the quality of life. The main pathogenic mechanism is the breakdown of cutaneous barrier integrity, which is associated with systemic inflammatory immunologic disorders. Atopic dermatitis involves numerous immunologic, allergic, respiratory, and ophthalmologic comorbidities that develop through similar intricate pathogenic phenomena. The atopic march represents the evolution in time of various allergic diseases, of which food allergies often cause the first manifestations of atopy, even from a very young age. Chronic inflammation translated through specific markers, next to increased immunoglobulin E (IgE) serum levels and heterogenous clinical manifestations, argue for the inclusion of atopic dermatitis in the systemic disease category.

Download Full-text